Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 29

recruiting
3 968
countries
28
conditions
2 103

638 trials match your criteria

Neoplasm malignant

Not recruiting

Phase 1 safety and dose-finding study of NG-350A plus pembrolizumab in patients with metastatic cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Osteoarthritis

Not recruiting

Safety, tolerability and pharmacokinetics of intra‑articular 4P‑004 versus sodium chloride placebo in patients with knee osteoarthritis (grade 2‑4)

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Liraglutide

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cabozantinib

Metastatic neoplasm

Not recruiting

Phase 1 Study of NG-641 with Nivolumab and Pembrolizumab in Patients with Metastatic or Advanced Epithelial Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate

Ovarian cancer

Not recruiting

Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tuvusertib
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib

Factor VIII deficiency+1

Not recruiting

A study looking at the safety of switching from emicizumab to denecimig in adults and adolescents with haemophilia A with or without inhibitors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:VX-407

Neoplasm

Not recruiting

A Study of GSK4524101 and Niraparib for Adults with Advanced Solid Tumors or Metastatic Breast Cancer with BRCA Gene Changes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GSK4524101A

A study to test how well empagliflozin works and how safe it is for children and teenagers with chronic kidney disease

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Empagliflozin

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.